Pure Global

A Study of IBI363 in Subjects With Advanced Solid Malignancies - Trial NCT06281678

Access comprehensive clinical trial information for NCT06281678 through Pure Global AI's free database. This Phase 2 trial is sponsored by Innovent Biologics (Suzhou) Co. Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 160 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06281678
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06281678
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of IBI363 in Subjects With Advanced Solid Malignancies
A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies

Study Focus

Solid Tumors

IBI363

Interventional

drug

Sponsor & Location

Innovent Biologics (Suzhou) Co. Ltd.

Fairway, United States of America

Timeline & Enrollment

Phase 2

Mar 01, 2024

Dec 31, 2026

160 participants

Primary Outcome

Objective response rate (ORR)

Summary

This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety
 and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid
 malignancies.

ICD-10 Classifications

Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm of other connective and soft tissue
Carcinoma in situ, unspecified
Malignant neoplasms
Malignant neoplasm: Parametrium

Data Source

ClinicalTrials.gov

NCT06281678

Non-Device Trial